PAREXEL International

Astra Zeneca

D8111R00003

A Phase IV Non-Interventional Enhanced Active Surveillance Study of Adults Vaccinated with VAXZEVRIA (AZD1222)

Summary Report for 1st Interim Analysis

PAREXEL Project Number: AZD257664

Author: PPD
Version 2.0
Date: 15Sept2021

CCI

TABLE OF CONTENTS

CCI

LIST OF TABLES AND FIGURES

D8111R00003 - IA#1: Table of Contents

(page numbers refer to Appendix A which contains all TFLs for this study)

CCI

LIST OF DATA LISTINGS

(page number refers to Appendix A which contains all TFLs for this study)

CCI

1 STUDY OVERVIEW

The enhanced active surveillance study was planned as a group of three studies across three regions, the UK, US and Europe. The goal was to recruit 30,000 subjects in France, Germany, Spain, and Sweden within 4 weeks of the first dose. The EAS planned for the EU (D8111R00003) was designed to recruit 15,000 subjects of the 30,000 total.

However, the study is facing severe recruitment challenges due to National Immunization Technical Advisory Group (NITAG) recommendations restricting Vaxzevria use to elderly age groups (≥55 for France, ≥60 for Germany, 60-69 for Spain, and ≥65 for Sweden) that have already achieved high vaccination coverage with at least one dose. Thus, vaccination with Vaxzevria in these countries is being effectively phased out and remaining doses are being used almost exclusively for completion of vaccination schedules instead of first dose administrations.

AstraZeneca proposed in June 2021 to amend the protocol to extend the recruitment window through the second dose, but this proposal was not endorsed.

2 SYNOPSIS

The following summarises and highlights the key significant results contained within this report:

A total of 27 participants were enrolled to this study at database extract date of which 7 (25.9%) did enrol within 7 days of 1st dose of Vaxzevria (AZD1222). 23 participants (85.2%) did complete week 1 of follow-up.

PPD

Until database cut, no SAEs, AESIs, AEFIs have been reported.

3 DATA CUT OFF

Data cut-off for this report was 30Jun2021.

4 STUDY SUBJECTS

4.1 Disposition of Subjects

The source documents for this section are tables 14.1.1 and 14.1.2.

A total of 27 participants were enrolled to this study at database extract date of which 7 (25.9%) did enrol within 7 days of 1st dose of Vaxzevria (AZD1222). 23 participants (85.2%) did complete week 1 of follow-up.

CCI

PPD

5 DEMOGRAPHIC AND OTHER BASELINE CHARACTERISTICS

5.1 Demographic Characteristics overall

The source document for this section is table 14.2.1.

Of the 27 participants enrolled, 7 have entered information about demographic and baseline characteristics:

4 (57.1%) participants are male and 3 (42.9%) female; PPD . The mean age of the study participants is 58.1 years, the median is 62.0 years. The youngest participant is PPD yo, the oldest PPD yo.

The mean of participants' height is 177.4 cm, the median 182.0 cm where the shortest participant is PPD cm, the tallest PPD cm. As for weight, the mean is 87.7 kg, the median 84.0 kg where the lightest participant is PPD kg, the heaviest PPD kg.

The BMI (kg/m2) of the participant population results as 27.9 (mean) and 29.4 (median), with a minimum of PPD and a maximum of PPD.

PPD

PPD

5.2 Demographic Characteristics for PPD participants

The source document for this section is table 14.2.4.

All PPD have entered information about demographic and baseline characteristics:

PPD participants are male and PPD is female. The mean age of PPD participants is 58.7 years, the median is PPD years. The youngest participant is PPD yo, the oldest PPD yo.

The mean of participants' height is 175.7 cm, the median PPD cm where the shortest participant measures PPD cm, the tallest PPD cm. As for weight, the mean is 98.7 kg, the median PPD kg where the lightest participant weighs PPD kg, the heaviest PPD kg.

CCI

The BMI (kg/m2) of the participant population results as 31.8 (mean) and PPD (median), with a minimum of PPD and a maximum of PPD.

PPD

PPD

5.3 Demographic Characteristics for participants with PPD

The source document for this section is table 14.2.5.

PPD

6 EFFICACY EVALUATION

Not applicable.

7 SAFETY EVALUATION

7.1 Extent of Exposure

Of 27 participants enrolled, 23 have completed 1 week after 1st dose of Vaxzevria (AZD1222).

7.2 Deaths

No deaths have been reported until today.

7.3 Adverse Events

7.3.1 Overview of Adverse Events

No Adverse Events have been reported until the date of database extract.

7.3.2 Serious Adverse Events

No Serious Adverse Events have been reported until the date of database extract.

7.3.3 Adverse Events Reported as Reason for Study Treatment Discontinuation

Not applicable.

7.3.4 Treatment Emergent Adverse Events of Special Interest

No Adverse Events of Special Interest have been reported until the date of database extract.

7.3.5 Adverse Events Following Immunization

No Adverse Events Following Immunization have been reported until the date of database extract.

7.4 Clinical Laboratory Evaluation

Not applicable.

7.5 ECG, Vital Signs and Physical Characteristics

Not applicable.

CCI [redacted]

APPENDIX A: UNBLINDED TABLES AND FIGURES

CCI [redacted]

SIGNATURE PAGE

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature

Document Name: d8111r00003-report-1st-ia		
Document Title:	D8111R00003 Report 1st IA	
Document ID:	CCI [redacted]	
Version Label:	2.0 CURRENT LATEST APPROVED	
Server Date **(dd-MMM-yyyy HH:mm 'UTC'Z)**	**Signed by**	**Meaning of Signature**
20-Sep-2021 17:01 UTC	PPD	Qualified Person Approval

Notes: (1) Document details as stored in ANGEL, an AstraZeneca document management system.

D8111R00003 - IA#1: Table of Contents

Table 14.1.1 Disposition

	Overall (N=27) n(%)
All participants enrolled[a]	27
Participants enrolled within 7 days after first dose of VAXZEVRIA (AZD1222)[a]	7 (25.9)
Participants who completed follow-up period:	
1 week	23 (85.2)

[a] Informed consent received.
Percentages determined using number of participants enrolled as denominator.

/projects/astzn257664/stats/interim/prog/tables/t_disp.SAS/26JUL2021/09:36
Database Extract Date: 30JUN2021

Table 14.1.2 Analysis sets

	Overall (N=27) n(%)
Full analysis set[a]	27
Primary analysis set[b]	7 (25.9)
PPD	

[a] Defined as all participants enrolled.
[b] Defined as all participants enrolled within 7 days of first dose of VAXZEVRIA(AZD1222).

/projects/astzn257664/stats/interim/prog/tables/t_analysis_sets.SAS/26JUL2021/09:37
Database Extract Date: 30JUN2021

Table 14.2.1 Key demographic and baseline characteristics - Primary Analysis Set[a]

		Total (N=7) n(%)
Age (years)	N	7
	Mean (95% CI)[b]	58.1 (49.1 - 67.2)
	Min	PPD
	Median	62.0
	Max	PPD
Gender, n (%)	Female	3 (42.9)
	Male	4 (57.1)
PPD		
Height (cm)	N	7
	Mean (95% CI)[b]	177.4 (167.0 - 187.9)
	Min	PPD
	Median	182.0
	Max	PPD

Max Maximum. Min Minimum. N Number of subjects in analysis set. n Number of subjects included in analysis.
[a] Informed consent received.
[b] NC due to low participant number.

/projects/astzn257664/stats/interim/prog/tables/t_demog_char_prim.SAS/26JUL2021/09:36
Database Extract Date: 30JUN2021

Table 14.2.1 Key demographic and baseline characteristics - Primary Analysis Set[a]

		Total (N=7) n(%)
Weight (kg)	N	7
	Mean (95% CI)[b]	87.7 (78.2 - 97.2)
	Min	PPD
	Median	84.0
	Max	PPD
BMI (kg/m2)	N	7
	Mean (95% CI)[b]	27.9 (25.2 - 30.6)
	Min	PPD
	Median	29.4
	Max	PPD
Country of birth, n (%)	PPD	PPD
Country of residence, n (%)	PPD	PPD

Max Maximum. Min Minimum. N Number of subjects in analysis set. n Number of subjects included in analysis.
[a] Informed consent received.
[b] NC due to low participant number.

/projects/astzn257664/stats/interim/prog/tables/t_demog_char_prim.SAS/26JUL2021/09:36
Database Extract Date: 30JUN2021

Table 14.2.1 Key demographic and baseline characteristics - Primary Analysis Set[a]

		Total (N=7) n(%)
Employment status, n (%)	PPD	
Smoking status/Smoking history, n (%)	PPD	

Max Maximum. Min Minimum. N Number of subjects in analysis set. n Number of subjects included in analysis.
[a] Informed consent received.
[b] NC due to low participant number.

/projects/astzn257664/stats/interim/prog/tables/t_demog_char_prim.SAS/26JUL2021/09:36
Database Extract Date: 30JUN2021

Table 14.2.2 Key demographic and baseline characteristics - Subpopulation of pregnant women

	Total (N=0) n(%)
No data to report	

Max Maximum. Min Minimum. N Number of subjects in analysis set. n Number of subjects included in analysis.

/projects/astzn257664/stats/interim/prog/tables/t_demog_char_preg.SAS/26JUL2021/09:36
Database Extract Date: 30JUN2021

Table 14.2.3 Key demographic and baseline characteristics - Subpopulation of breastfeeding women

	Total (N=0) n(%)
No data to report	

Max Maximum. Min Minimum. N Number of subjects in analysis set. n Number of subjects included in analysis.

Table 14.2.4 Key demographic and baseline characteristics - PPD

		Total (PPD) n(%)
Age (years)	N	PPD
	Mean (95% CI)[a]	58.7 (NC, NC)
	Min	PPD
	Median	PPD
	Max	PPD
Gender, n (%)	Female	PPD
	Male	PPD
PPD	PPD	PPD
Height (cm)	N	PPD
	Mean (95% CI)[a]	175.7 (NC, NC)
	Min	PPD
	Median	PPD
	Max	PPD

Max Maximum. Min Minimum. N Number of subjects in analysis set. n Number of subjects included in analysis.
[a] NC due to low participant number.

/projects/astzn257664/stats/interim/prog/tables/t_demog_char_imm.SAS/26JUL2021/09:36
Database Extract Date: 30JUN2021

Table 14.2.4 Key demographic and baseline characteristics - PPD

		Total (PPD) n(%)
Weight (kg)	N	PPD
	Mean (95% CI)[a]	98.7 (NC, NC)
	Min	PPD
	Median	PPD
	Max	PPD
BMI (kg/m2)	N	PPD
	Mean (95% CI)[a]	31.8 (NC, NC)
	Min	PPD
	Median	PPD
	Max	PPD
Country of birth, n (%)	PPD	PPD
Country of residence, n (%)	PPD	PPD
Employment status, n (%)	PPD	

Max Maximum. Min Minimum. N Number of subjects in analysis set. n Number of subjects included in analysis.
[a] NC due to low participant number.

Table 14.2.4 Key demographic and baseline characteristics - PPD

	Total (PPD) n(%)
Smoking status/Smoking history, n (%)	
PPD	

Max Maximum. Min Minimum. N Number of subjects in analysis set. n Number of subjects included in analysis.
[a] NC due to low participant number.

/projects/astzn257664/stats/interim/prog/tables/t_demog_char_imm.SAS/26JUL2021/09:36
Database Extract Date: 30JUN2021

Table 14.2.5 Key demographic and baseline characteristics - PPD
disorders

		Total (PPD) n(%)
Age (years)		
Gender, n (%)	PPD	PPD
Height (cm)		
Weight (kg)		

Max Maximum. Min Minimum. N Number of subjects in analysis set. n Number of subjects included in analysis.
[a] NC due to low participant number.

Table 14.2.5 Key demographic and baseline characteristics - PPD disorders

		Total (PPD) n(%)
BMI (kg/m2)	PPD	
Country of birth, n (%)	PPD	PPD
Country of residence, n (%)	PPD	PPD
Employment status, n (%)	PPD	
Smoking status/Smoking history, n (%)	PPD	

Max Maximum. Min Minimum. N Number of subjects in analysis set. n Number of subjects included in analysis.
[a] NC due to low participant number.

/projects/astzn257664/stats/interim/prog/tables/t_demog_char_aii.SAS/26JUL2021/09:37
Database Extract Date: 30JUN2021

Table 14.2.6 Key demographic and baseline characteristics - Subpopulation of frail participants with comorbidities[a]

	Total (N=0) n(%)
No data to report	

Max Maximum. Min Minimum. N Number of subjects in analysis set. n Number of subjects included in analysis.
[a] Refer to SAP 1.0 (28May2021), table 1.

/projects/astzn257664/stats/interim/prog/tables/t_demog_char_como.SAS/26JUL2021/09:37
Database Extract Date: 30JUN2021

Table 14.3.1 Total number of SAEs reported during follow-up interval - Primary Analysis Set

Follow-up interval	Number of participants[a]	Number of participants who experienced SAEs[b]	Total number of SAEs[c]	Percentage/Proportion of participants[d] (95% CI[e])
No data to report				

[a] Number of participants who completed considered follow-up interval.
[b] Number of participants who experienced at least one event in the considered follow-up interval.
[c] Total number of events reported in the considered follow-up interval.
[d] Calculated as the proportion of participants who reported an event among all VAXZEVRIA (AZD1222) vaccinated participants who completed considered follow-up interval. Subjects with multiple events in the same category are counted only once in that category. Subjects with events in more than 1 category are counted once in each of those categories.
[e] Asymptotic / NC due to low participant number. SAE Serious AE.

/projects/astzn257664/stats/interim/prog/tables/t_ae_fup.SAS/26JUL2021/09:37
Database Extract Date: 30JUN2021

Table 14.3.2 Total number of AESIs reported during follow-up interval - Primary Analysis Set

Follow-up interval	Number of participants[a]	Number of participants who experienced AESIs[b]	Total number of AESIs[c]	Percentage/Proportion of participants[d] (95% CI[e])
No data to report				

[a] Number of participants who completed considered follow-up interval.
[b] Number of participants who experienced at least one event in the considered follow-up interval.
[c] Total number of events reported in the considered follow-up interval.
[d] Calculated as the proportion of participants who reported an event among all VAXZEVRIA (AZD1222) vaccinated participants who completed considered follow-up interval. Subjects with multiple events in the same category are counted only once in that category. Subjects with events in more than 1 category are counted once in each of those categories.
[e] Asymptotic / NC due to low participant number. AESI Adverse event of special interest.

/projects/astzn257664/stats/interim/prog/tables/t_ae_fup.SAS/26JUL2021/09:37
Database Extract Date: 30JUN2021

Table 14.3.3 Total number of medically-attended AEFIs reported during follow-up interval - Primary Analysis Set

Follow-up interval	Number of participants[a]	Number of participants who experienced medically-attended AEFIs[b]	Total number of medically-attended AEFIs[c]	Percentage/Proportion of participants[d] (95% CI[e])
No data to report				

[a] Number of participants who completed considered follow-up interval.
[b] Number of participants who experienced at least one event in the considered follow-up interval.
[c] Total number of events reported in the considered follow-up interval.
[d] Calculated as the proportion of participants who reported an event among all VAXZEVRIA (AZD1222) vaccinated participants who completed considered follow-up interval. Subjects with multiple events in the same category are counted only once in that category. Subjects with events in more than 1 category are counted once in each of those categories.
[e] Asymptotic / NC due to low participant number. AEFI Adverse event following immunization.

/projects/astzn257664/stats/interim/prog/tables/t_ae_fup.SAS/26JUL2021/09:37
Database Extract Date: 30JUN2021

Table 14.4.1 Incidence rate of an SAE during follow-up interval - Primary Analysis Set

Follow-up interval	Total number of participants[a]	Number of participants who experienced an SAE[b]	SAE rate as per 100 pt-yrs[c]	95% CI[d]
No data to report				

[a] Number of all VAXZEVRIA (AZD1222) vaccinated participants who completed considered follow-up interval.
[b] Number of participants who experienced at least one event in the considered follow-up interval.
[c] Defined as the total number of events reported in the considered follow-up interval divided by the total person-time at risk, i.e. the time period between first dose of VAXZEVRIA (AZD1222) and the end of the considered follow-up interval. Participants with multiple events are counted only once
[d] Asymptotic. / NC due to low participant number.
AE Adverse event. SAE Serious AE. Pt-yrs Participant-Years.

/projects/astzn257664/stats/interim/prog/tables/t_ae_incrate.SAS/26JUL2021/09:37
Database Extract Date: 30JUN2021

Table 14.4.2 Incidence rate of an AESI during follow-up interval - Primary Analysis Set

Follow-up interval	Total number of participants[a]	Number of participants who experienced an AESI[b]	AESI rate as per 100 pt-yrs[c]	95% CI[d]
No data to report				

[a] Number of all VAXZEVRIA (AZD1222) vaccinated participants who completed considered follow-up interval.
[b] Number of participants who experienced at least one event in the considered follow-up interval.
[c] Defined as the total number of events reported in the considered follow-up interval divided by the total person-time at risk, i.e. the time period between first dose of VAXZEVRIA (AZD1222) and the end of the considered follow-up interval. Participants with multiple events are counted only once
[d] Asymptotic. / NC due to low participant number.
AE Adverse event. AESI Adverse event of special interest. Pt-yrs Participant-Years.

/projects/astzn257664/stats/interim/prog/tables/t_ae_incrate.SAS/26JUL2021/09:37
Database Extract Date: 30JUN2021

Table 14.4.3 Incidence rate of a medically-attended AEFI during follow-up interval - Primary Analysis Set

Follow-up interval	Total number of participants[a]	Number of participants who experienced a medically-attended AEFI[b]	Medically-attended AEFI rate as per 100 pt-yrs[c]	95% CI[d]
No data to report				

[a] Number of all VAXZEVRIA (AZD1222) vaccinated participants who completed considered follow-up interval.
[b] Number of participants who experienced at least one event in the considered follow-up interval.
[c] Defined as the total number of events reported in the considered follow-up interval divided by the total person-time at risk, i.e. the time period between first dose of VAXZEVRIA (AZD1222) and the end of the considered follow-up interval. Participants with multiple events are counted only once
[d] Asymptotic. / NC due to low participant number.
AE Adverse event. AEFI adverse event following immunization. Pt-yrs Participant-Years.

/projects/astzn257664/stats/interim/prog/tables/t_ae_incrate.SAS/26JUL2021/09:37
Database Extract Date: 30JUN2021

Table 14.4.4 Paticipants who experienced more than one SAE, AESI or medically-attended AEFI - Primary Analysis Set

Type of event	Follow-up interval	Number of events	Number of participants (%)
No data to report			

AE Adverse event. SAE Serious AE. AESI Adverse event of special interest. AEFI adverse event following immunization.

/projects/astzn257664/stats/interim/prog/tables/t_ae_multiple.SAS/26JUL2021/09:38
Database Extract Date: 30JUN2021

Listing 1.1 Serious AEs / AESIs / medically-attended AEFIs with death as possible outcome - Key Subject Information

Subj. ID	Age/Sex	Type of Event[a]	Dictionary-derived Term[b]	Study day of start	Duration (days)	Intensity	Outcome[c]
No data to report							

[a] Indicate if SAE, AESI or medically-attended AEFI.
[b] Coded following MedDRA version 24.0.
[c] Include death as possible outcome.

/projects/astzn257664/stats/interim/prog/listings/l_ae_subj_info.SAS/26JUL2021/09:38
Database Extract Date: 30JUN2021